Emergence of <i>ERBB2</i> Mutation as a Biomarker and an Actionable Target in Solid Cancers.

Subramanian, Janakiraman; Katta, Archana; Masood, Ashiq; Vudem, Dashavantha Reddy; Kancha, Rama Krishna

Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers.

Subramanian, Janakiraman; Katta, Archana; Masood, Ashiq; Vudem, Dashavantha Reddy; Kancha, Rama Krishna.

Afiliación

Subramanian J; Division of Oncology, Saint Luke's Cancer Institute, Kansas City, Missouri, USA jsubramanian@saint-lukes.org ickrishna@gmail.com.
Katta A; Center for Precision Oncology, Saint Luke's Cancer Institute, Kansas City, Missouri, USA.
Masood A; Molecular Medicine and Therapeutics Laboratory, Centre for Plant Molecular Biology, Osmania University, Hyderabad, India.
Vudem DR; Division of Oncology, Saint Luke's Cancer Institute, Kansas City, Missouri, USA.
Kancha RK; Center for Precision Oncology, Saint Luke's Cancer Institute, Kansas City, Missouri, USA.

Oncologist ; 24(12): e1303-e1314, 2019 12.

Article en En | MEDLINE | ID: mdl-31292270

Asunto(s)

Mutación; Neoplasias/genética; Receptor ErbB-2/genética; Biomarcadores de Tumor/genética; Biomarcadores de Tumor/metabolismo; Humanos; Terapia Molecular Dirigida; Neoplasias/tratamiento farmacológico; Receptor ErbB-2/metabolismo

Palabras clave

ERBB2 mutation; Gastrointestinal cancer; HER2; Nonsmall cell lung cancer; Tyrosine kinase

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptor ErbB-2 / Mutación / Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google